Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Michaela J. Sommer"'
Autor:
Corinna N. Lang, Michaela J. Sommer, Merja A. Neukamm, Dawid L. Staudacher, Alexander Supady, Christoph Bode, Daniel Duerschmied, Achim Lother
Publikováno v:
Intensive Care Medicine Experimental, Vol 8, Iss 1, Pp 1-8 (2020)
Abstract Background 3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) abuse is frequent, and overdosing might cause severe and eventually lethal multi-organ failure. To date, there is no causal therapy of MDMA intoxication and removal of MDMA f
Externí odkaz:
https://doaj.org/article/399f2c47f62c4c64bc6642c6871b12e0
Autor:
Paul Biever, Dawid L. Staudacher, Michaela J. Sommer, Hannah Triebel, Merja A. Neukamm, Christoph Bode, Alexander Supady, Achim Lother
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 2, Pp n/a-n/a (2021)
Abstract Both antiviral treatment with remdesivir and hemoadsorption using a CytoSorb® adsorption device are applied in the treatment of severe COVID‐19. The CytoSorb® adsorber consists of porous polymer beads that adsorb a broad range of molecul
Externí odkaz:
https://doaj.org/article/bd1ec997d173477b912d5f223d00cd81
Autor:
Arianna Giorgetti, Michaela J. Sommer, Markus Große Perdekamp, Maurice Wilde, Volker Auwärter
Publikováno v:
Forensic Toxicology. 40:180-188
Purpose Designer benzodiazepines (DBZDs) increasingly emerged on the novel psychoactive substance (NPS) market in the last few years. They are usually sold as readily available alternatives to prescription benzodiazepines (BZDs) or added to counterfe
Autor:
Michaela J. Sommer, Sebastian Halter, Verena Angerer, Volker Auwärter, Florian Eyer, Gesine Liebetrau, Martin Ebbecke, Maren Hermanns-Clausen
Publikováno v:
Clinical toxicology (Philadelphia, Pa.). 60(10)
New psychoactive substances (NPS) have become an ongoing threat to public health. To prevent the emergence and spread of NPS, a new German law, the 'NpSG' took effect in November 2016. This study presents an overview of analytically confirmed synthet
Publikováno v:
Toxicology Letters. 320:109-112
Background Since 2016 an increase has been observed in the availability of new synthetic opioids (NSO) in Europe. Cyclopropylfentanyl is a very potent and selective μ-opioid agonist, which was reported for the first time in August 2017 in Europe. Me